Compare
Clene Inc. vs Scienture Holdings, Inc. vs Yarrow Bioscience, Inc. vs BioXcel Therapeutics, Inc.
| Latest fiscal year | Clene Inc. CLNN | Scienture Holdings, Inc. SCNX | Yarrow Bioscience, Inc. YARW | BioXcel Therapeutics, Inc. BTAIQ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $200.0K | $431.6K | $570.0K | $642.0K |
| Revenue growth (YoY) | -41.5% | +215.9% | +13.8% | -71.7% |
| Gross margin | 78.5% (computed) | 76.8% | n/a | 74.5% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$26.17M | -$41.51M | -$26.48M | -$69.90M |
| EPS (Diluted) | n/a | -$2.70 | -$0.62 | -$5.73 |
| Operating cash flow | -$18.55M | -$13.38M | -$33.12M | -$57.62M |
| Free cash flow | -$18.59M | n/a | -$33.12M | -$57.62M |
| Cash & equivalents | $5.19M | $6.66M | $24.03M | $28.41M |
| Total assets | $18.13M | $84.18M | $30.16M | $44.92M |
| Total liabilities | $35.72M | $14.06M | $2.40M | $140.38M |
| Shareholders' equity | -$17.59M | $70.12M | $27.77M | -$95.46M |
| Return on year-end equity | n/a | -59.2% | -95.4% | n/a |
| Shares outstanding | 10.85M | 40.63M | 33.32M | 22.33M |
Revenue, most recent five fiscal years
| Fiscal year | Clene Inc. | Scienture Holdings, Inc. | Yarrow Bioscience, Inc. | BioXcel Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $200.0K Ended 2025-12-31 | $431.6K Ended 2025-12-31 | $570.0K Ended 2025-12-31 | $642.0K Ended 2025-12-31 |
| 1 year earlier | $342.0K Ended 2024-12-31 | $136.6K Ended 2024-12-31 | $501.0K Ended 2024-12-31 | $2.27M Ended 2024-12-31 |
| 2 years earlier | $654.0K Ended 2023-12-31 | $1.36M Ended 2023-12-31 | $424.0K Ended 2023-12-31 | $1.38M Ended 2023-12-31 |
| 3 years earlier | $473.0K Ended 2022-12-31 | $10.25M Ended 2022-12-31 | $477.0K Ended 2022-12-31 | $375.0K Ended 2022-12-31 |
| 4 years earlier | $723.0K Ended 2021-12-31 | $9.89M Ended 2021-12-31 | $931.0K Ended 2021-12-31 | n/a |